Bausch + Lomb Corporation

NYSE:BLCO

Medical - Instruments & Supplies

Healthcare
$20.95 +0.27%

+$0.04 today

Market cap
$7.49B
Beta
0.57
P/E (TTM)
-24.2
EPS (TTM)
-$0.62
52W Low $11.58High $18.92

Volume 0.51M

Average 0.46M

BLCO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Bausch + Lomb CorporationNYSE: BLCO

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows in line with its trailing trend

Q2 FY2026 revenue of $1.39B rose 8.7% year over year, in line with the +8.8% change in trailing-twelve-month revenue. Sequentially, it rose 11.7% from the prior quarter. Over 3 fiscal years it compounded at +10.6% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 11 analysts of $5.5B (+7.8%) for the fiscal year ending Dec 2026, a step up from the +6.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.39B+11.7% QoQ
Last fiscal yearDec 2025
$5.1B+6.5% YoY
LTMJun 2026
$5.32B+8.8% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.7%+7.1%-1.6 pp
1 year+6.5%+7.8%+1.4 pp
3-year CAGR+10.6%+6.4%-4.2 pp
5-year CAGR+6.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
5.1B USD
Year-over-year change
+6.5%
4-year CAGR
+7.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How BLCO compares with its peers on the latest reported figures

  • BLCO's LTM Jun 2026 revenue of $5.32B is the 2nd highest of the 10 companies compared; the peer median is $897.76M.
  • Its year-over-year change of +8.8% is the 5th highest of 9, against a peer median of -2.7%.
  • Over three fiscal years its annual growth of +10.6% compares with a peer median of +29.3%.
BLCO Competitors Peer median
Revenue for BLCO and competitors
Company Period LTM YoY 3-year CAGR
OSCROscar Health, Inc.LTM Jun 2026$15.32B +42.8%+41.6%
BLCOBausch + Lomb CorporationLTM Jun 2026$5.32B +8.8%+10.6%
TFXTeleflex IncorporatedLTM Jun 2026$2.6B -14.5%-10.6%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$1.61B +9.2%+9.6%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$1.01B -42.8%+35.3%
TGTXTG Therapeutics, Inc.LTM Sep 2026$897.76M +68.8%+504.9%
GKOSGlaukos CorporationLTM Jun 2026$612.84M +41.5%+21.5%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$450.82M -45.6%+23.3%
CRSPCRISPR Therapeutics AGLTM Sep 2026$25.17M -33.1%+100.4%
PCVXVaxcyte, Inc.LTM Jun 2026$0 ——
Peer median (excluding BLCO) $897.76M-2.7%+29.3%

Competitors are the stored peer set for BLCO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.77B3.77B4.15B4.79B5.1B
Cost of Revenue1.47B1.52B1.64B1.87B2.31B
Gross Profit2.3B2.25B2.5B2.92B2.79B
Gross Margin61.0%59.7%60.4%60.9%54.8%
Research & Development271M307M324M343M371M
Selling, General & Admin1.39B1.48B1.74B2.08B2.23B
Operating Expenses1.97B2.04B2.37B2.76B2.61B
Depreciation & Amortization415M379M382M436M421M
EBITDA733M598M499M601M535M
EBITDA Margin19.5%15.9%12.0%12.5%10.5%
Operating Income329M207M130M162M188M
Operating Margin8.7%5.5%3.1%3.4%3.7%
Interest Income06M15M15M12M
Interest Expense0146M283M399M431M
Other Income / Expenses(11M)(134M)(296M)(396M)(505M)
Income Before Tax318M73M(166M)(234M)(317M)
Pre-Tax Margin8.4%1.9%-4.0%-4.9%-6.2%
Income Tax Expense125M58M82M71M35M
Net Income182M6M(260M)(317M)(360M)
Net Margin4.8%0.2%-6.3%-6.6%-7.1%
EPS (Basic)0.520.04(0.74)(0.90)(1.02)
EPS (Diluted)0.520.04(0.74)(0.90)(1.02)
Weighted Avg Shares350M350M350.5M351.8M353.8M
Weighted Avg Shares (Diluted)350M350M350.5M351.8M353.8M

Bausch + Lomb Corporation

NYSE:BLCO

Intrinsic Alpha fair value

Locked

Current Price

$20.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.